To reduce the incidence of primary and secondary nonresponse and improve its efficiency in patients with IBD, it is highly clinically and economically relevant to offer anti-TNF bioagents to IBD patients who will benefit from anti-TNF biological therapy given their individual condition (23–29). Here, TNF is linked to inflammatory bowel disease.